Objectives: We aimed to reveal the treatments of patients with muscle-invasive bladder cancer and the results of treatments in our center. We also evaluated factors affecting progression-free survival and overall survival. Methods: The patients are divided into 5 categories based on the treatment types: (i) only surgery, (ii) surgery + adjuvant chemotherapy, (iii) neoadjuvant chemotherapy + surgery, (iv) neoadjuvant chemotherapy + chemoradiotherapy, (v) definitive chemoradiotherapy. Results: A total of 118 patients were included in this study. 3-year progression-free survival rate was 34% in only surgery group (n=42), 53% in surgery + adjuvant chemotherapy (n=40), 45% in neoadjuvant chemotherapy + surgery (n=8), 0% in neoadjuvant chemotherapy + chemoradiotherapy (n=6) and 26% in definitive chemoradiotherapy (n=21). 5-year survival rate was respectively 31%, 44%, 53%, 25%, and 19% in these groups. ECOG performance status of 1-3, pathological T stage 3-4, surgical margin positivity, and not receiving adjuvant chemotherapy were independent risk factors for disease progression. Pathological T stage 3-4 (HR:8.2 CI 2.4-27.4, p<0.01) and receiving incomplete chemotherapy (HR:3.9 CI 1.9-8, p<0.01) in adjuvant/neoadjuvant setting were independent risk factors for mortality. Conclusion: Adjuvant chemotherapy and neoadjuvant chemotherapy were not used sufficiently in muscle-invasive bladder cancer. Surgery + adjuvant chemotherapy showed a survival advantage over only surgery and chemoradiotherapy. The pathological T stage is the best prognostic factor. Receiving complete systemic treatment in an adjuvant / neoadjuvant setting is related to overall survival. Keywords: Bladder cancer, muscle-invasive, neoadjuvant chemotherapy, survival, treatment
Corresponding Author: Elif Atag